Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(02): 127-141
DOI: 10.4103/ijmpo.ijmpo_61_17
Original Article

Nonsteroidal Anti-inflammatory Drugs and Clinical Outcomes among Men with Prostate Cancer: A Systematic Review and Meta-analysis

Divyesh Thakker
Novartis Healthcare, Hyderabad, Telangana, India
,
Amit D Raval
Healthcore, Inc. Wilmington, Wilmington, Delaware, USA
,
Nilixa Raval
Independent Researcher, Wilmington, Delaware, USA
,
Ami Vyas
College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) have shown properties of inhibiting the progression of prostate cancer (PCa) in preclinical studies. However, epidemiological studies yield mixed results on the effectiveness of NSAIDs in PCa. Objective: The objective of this study was to determine the effect of NSAID use on clinical outcomes in PCa using systematic review and meta-analysis. Methods: Original articles published until the 1st week of October, 2016, were searched in electronic databases (Medline-Ovid, PubMed, Scopus, The Cochrane Library, and Web of Science) for studies on NSAID use in PCa. The main clinical outcomes for the review were: PCa-specific (PCM) and all-cause mortality (ACM), biochemical recurrence (BCR), and metastases. Meta-analysis was performed to calculate the pooled hazard ratio (pHR) and their 95% confidence interval (95% CI). Heterogeneity between the studies was examined using I2 statistics. Appropriate subgroup analyses were conducted to explore the reasons for heterogeneity. Results: Out of 4216 retrieved citations, 24 observational studies and two randomized controlled studies with a total of 89,436 men with PCa met the inclusion criteria. Overall, any NSAID use was not associated with PCM, ACM, and BCR, with significant heterogeneity. Neither precancer treatment aspirin use (pHR: 1.00, 95% CI: 0.83, 1.19, P = 0.97, 5 studies, I2: 51%) nor postcancer treatment aspirin use (pHR: 0.94, 95% CI: 0.72, 1.23, P = 0.67, 8 studies, I2: 86%) was associated with PCM. Similar findings, that is, no significant association was observed for NSAID use and ACM or BCR overall, and in subgroup by types of NSAID use, and NSAID use following radiation or surgery. Conclusion: Although NSAID use was not associated with ACM, PCM, or BCR among men with PCa, significant heterogeneity remained in the included studies even after subgroup analyses.

Keywords

Aspirin - biochemical recurrence - prostate cancer - prostate cancer-specific mortality


Publication History

Article published online:
23 June 2021

© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Globocan 2012 – Home. Available from: http://www.globocan.iarc.fr/Default.aspx. [Last accessed on 2016 Jun 04].
  • 2 Global Oncology Trend Report a Review of 2015 and Outlook to 2020.IMS Health; 2016. Available from: http://www.imshealth.com/en/thought-leadership/ims-institute/reports/global-oncology-trend-report-a-review-of-2015-and-outlook-to-2020 [Last accessed on 2016 Jun 04]
  • 3 Thun MJ, Blackard B. Pharmacologic effects of NSAIDs and implications for the risks and benefits of long-term prophylactic use of aspirin to prevent cancer. Recent Results Cancer Res 2009; 181: 215-21
    CrossrefPubMedGoogle Scholar
  • 4 Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med 2013; 24: 393-400
    CrossrefPubMedGoogle Scholar
  • 5 Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123-34
    CrossrefPubMedGoogle Scholar
  • 6 Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability Carcinogenesis 2009; 30: 1073-81
    CrossrefPubMed
  • 7 Kundu JK, Surh YJ. Inflammation: Gearing the Journey to Cancer. Vol.659. Proceedings 5th International Conference Environmental Mutagens Humam Population ICEMHP 2008; p: 15-30
    Google Scholar
  • 8 Liu Y, Chen JQ, Xie L, Wang J, Li T, He Y. et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: A systematic review and meta-analysis. BMC Med 2014; 12: 55
    CrossrefPubMedGoogle Scholar
  • 9 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097
    CrossrefPubMedGoogle Scholar
  • 10 von ElmE, Altman DG, Egger M, Pocock SJ, Gøtzsche PC. et al Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. BMJ 2007; 335: 806-8
    CrossrefPubMedGoogle Scholar
  • 11 Ottawa Hospital Research Institute. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. [Last accessed on 2016 Jun 04].
  • 12 Cochrane Handbook for Systematic Reviews of Interventions. Available from: http://www.handbook.cochrane.org/. [Last accessed on 2016 Apr 30].
  • 13 van HouwelingenHC, Arends LR, Stijnen T. Advanced methods in meta-analysis: Multivariate approach and meta-regression. Stat Med 2002; 21: 589-624
    CrossrefPubMedGoogle Scholar
  • 14 Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-93
    CrossrefPubMedGoogle Scholar
  • 15 Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008; 61: 991-6
    CrossrefPubMedGoogle Scholar
  • 16 Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. et al. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012; 30: 3540-4
    CrossrefPubMedGoogle Scholar
  • 17 Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: Results from caPSURE. BJU Int 2010; 106: 627-32
    CrossrefPubMedGoogle Scholar
  • 18 Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. et al. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011; 185: 1268-73
    CrossrefPubMedGoogle Scholar
  • 19 Forget P, Tombal B, Scholtès JL, Nzimbala J, Meulders C, Legrand C. et al. Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer?. Eur J Anaesthesiol 2011; 28: 830-5
    CrossrefPubMedGoogle Scholar
  • 20 Zaorsky NG, Li T, Cohen RJ, Horwitz EM, Uzzo RG, Viterbo R. et al. Aspirin use decreases the risk of prostate cancer recurrence after post-prostatectomy radiotherapy. J Radiat Oncol 2015; 4: 193-201
    CrossrefGoogle Scholar
  • 21 Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer 2010; 116: 1820-6
    CrossrefPubMedGoogle Scholar
  • 22 Flahavan EM, Bennett K, Sharp L, Barron TI. A cohort study investigating aspirin use and survival in men with prostate cancer. Ann Oncol 2014; 25: 154-9
    CrossrefPubMedGoogle Scholar
  • 23 Kontraros M, Varkarakis I, Ntoumas K, Deliveliotis C. Pathological characteristics, biochemical recurrence and functional outcome in radical prostatectomy patients on statin therapy. Urol Int 2013; 90: 263-9
    CrossrefPubMedGoogle Scholar
  • 24 Caon J, Paquette M, Hamm J, Pickles T. Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy?. Prostate Cancer 2014; 2014: 184297
    CrossrefPubMedGoogle Scholar
  • 25 Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association between use of β-blockers and prostate cancer-specific survival: A cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2013; 65: 635-41
    CrossrefPubMedGoogle Scholar
  • 26 Ishak-Howard MB, Okoth LA, Cooney KA. et al. Neonatal. Neonat 2013; 2: 4-7
    Google Scholar
  • 27 Jacobs CD, Chun SG, Yan J, Xie XJ, Pistenmaa DA, Hannan R. et al. Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biol Ther 2014; 15: 699-706
    CrossrefPubMedGoogle Scholar
  • 28 Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ, Gapstur SM. et al. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol 2014; 32: 3716-22
    CrossrefPubMedGoogle Scholar
  • 29 Assayag J, Pollak MN, Azoulay L. The use of aspirin and the risk of mortality in patients with prostate cancer. J Urol 2015; 193: 1220-5
    CrossrefPubMedGoogle Scholar
  • 30 Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial. Prostate 2015; 75: 1394-402
    CrossrefPubMedGoogle Scholar
  • 31 Zaorsky NG, Buyyounouski MK, Li T, Horwitz EM. Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Int J Radiat Oncol Biol Phys 2012; 84: e13-7
    CrossrefPubMedGoogle Scholar
  • 32 Agarwal G, Spuches J, Luchey A, Patel T, Pow-Sang J. The effect of NSAID use on disease progression in patients on active surveillance for prostate cancer. Ann Rheum Dis 2015; 193: e756
    Google Scholar
  • 33 Osborn VW, Chen SC, Weiner J, Schwartz D. Impact of aspirin on clinical outcomes for African American men with prostate cancer undergoing radiation. Tumori 2016; 102: 65-70
    CrossrefPubMedGoogle Scholar
  • 34 Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. et al. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004; 24: 3177-84
    Google Scholar
  • 35 Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila) 2012; 5: 1223-8
    CrossrefPubMedGoogle Scholar
  • 36 Stock DC, Groome PA, Siemens DR, Rohland SL, Sinha S. Effects of non-selective non-steroidal anti-inflammatory drugs on the aggressiveness of prostate cancer. Prostate 2008; 68: 1655-65
    CrossrefPubMedGoogle Scholar
  • 37 Cardwell CR, Flahavan EM, Hughes CM, Coleman HG, O'Sullivan JM, Powe DG. et al Low-dose aspirin and survival in men with prostate cancer: A study using the UK Clinical Practice Research Datalink. Cancer Causes Control 2014; 25: 33-43
    CrossrefPubMedGoogle Scholar
  • 38 Goluboff ET, Prager D, Rukstalis D, Giantonio B, Giantonio D, Madorsky M, Barken I. et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol 2001; 166: 882-6
    CrossrefPubMedGoogle Scholar
  • 39 D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 2008; 26: 2979-83
    CrossrefPubMedGoogle Scholar
  • 40 Daugherty S, Pfeiffer R, Ghazarian A, Izmirlian G, Prorok P, McGlynn K. Frequency of aspirin use and prostate cancer mortality among prostate cancer cases in the control arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Cancer Res 2013; 73: LB-15
    CrossrefGoogle Scholar
  • 41 Veitonmäki T, Murtola TJ, Talala K, Taari K, Tammela T, Auvinen A. et al Non-steroidal anti-inflammatory drugs and cancer death in the Finnish prostate cancer screening trial. PLoS One 2016; 11: e0153413
    CrossrefPubMedGoogle Scholar
  • 42 D'Amico AV, Kantoff PW, Chen MH. Aspirin and hormone therapy for prostate cancer. N Engl J Med 2007; 357: 2737-8
    CrossrefPubMedGoogle Scholar